Delivery of Full Dose CHOP Chemotherapy to Elderly Patients with Aggressive Non-Hodgkin's Lymphoma without G-CSF Support
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 35 (1-2) , 119-127
- https://doi.org/10.3109/10428199909145711
Abstract
Because of evidence that failure to deliver full dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) may compromise the outcome of elderly patients with aggressive non-Hodgkin's lymphoma (NHL), we attempted to deliver full dose CHOP to these patients. The objective of this review was to assess the relative received dose intensity (ARRDI), tox-icity and outcome of elderly patients treated with curative intent with CHOP at our centre. Charts were reviewed of all patients ≥265 years with newly diagnosed aggressive NHL referred to the Toronto-Sunnybrook Regional Cancer Centre (TSRCC) for initial management from 1990–1995 before routine use of G-CSF. Sixty eligible patients were identified. 31 received CHOP +/- radiation (XRT), 9 other curative treatment and 20, palliative treatment. The mean ARRDI calculated on 29/31 patients receiving CHOP was 86; 41%=1.0. 24%=90-99, 14%=75-89 and 21%=<.75. During 141 cycles of CHOP, 17 (12%) episodes of febrile neutropenia (FN) occurred in 14 (45%) patients and other grade 3/4 toxicity occurred in <10% of patients. There were 3 (10%) toxic deaths. Sixteen (52%) patients required a total of 29 admissions to hospital for FN (59%) or other causes. Of the 31 patients, 16 (52%) achieved a complete remission (CR), 7 (23%) a partial remission-I (PR-I), 2 (6%) a partial remission-2 (PR-2), 1 (3%) had no response (NR), 2 (6%) had progressive disease and 3 (10%) were not evaluable (NE). The median progression free survival (PFS) and overall survival (OS) were (16+) months and (24.5) months respectively. We found that physician biases resulted in the selection of; younger patients (median 71 vs. 80 years), patients with a better ECOG performance status (≥ 22, 13% vs. 50%) and patients with less co-morbid illness (42% vs. 90%) for attempt at curative treatment with CHOP chemotherapy. Age was never the sole reason for offering palliative treatment. In conclusion, a subset of patients over the age of 65 with aggressive NHL, who have a good performance status and minimal co-morbid illness can tolerate full dose CHOP chemotherapy without G-CSF support. Future strategies should emphasize full dose treatment with curative intent with minimization of both hematologic and non-hematologic toxicity. Clinical studies are required to determine whether routine G-CSF support will reduce toxicity or improve outcome in this group of patients.Keywords
This publication has 25 references indexed in Scilit:
- Treatment of aggressive Non‐Hodgkin's lymphoma in the elderlyAmerican Journal of Hematology, 1995
- Full Dose Chop Chemotherapy in Elderly Patients with Non-Hodgkin's LymphomaActa Oncologica, 1995
- Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histologyEuropean Journal Of Cancer, 1994
- Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderlyHematological Oncology, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Copp chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphomaHematological Oncology, 1993
- Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: A phase II studyHematological Oncology, 1991
- Pirarubicin, A Novel Derivative of Doxorubicin THP-COP Therapy for Non-Hodgkinʼs Lymphoma in the ElderlyAmerican Journal of Clinical Oncology, 1990
- Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patientsEuropean Journal of Cancer and Clinical Oncology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958